PD-L1 Antibody (YA4674)

Cell membrane,Early endosome membrane,Recycling endosome membrane,Nucleus,Cell membrane,Endomembrane system,Secreted

Tissue_specificity:It is highly expressed in the heart, skeletal muscle, placenta, and lungs. It is weakly expressed in the thymus, spleen, kidneys, and liver. It is expressed on activated T cells and B cells, dendritic cells, keratinocytes, and monocytes; it is widely expressed, with the highest expression in the lungs, liver, pituitary gland, and various peripheral blood cells (including neutrophils and certain subtypes of lymphocytes and myeloid cells) .

Induction:Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking

CD274 (PD-L1) has 4 isomers: Q9NZQ7-1: 33275 Da (predicted); Q9NZQ7-2: 20246 Da (predicted); Q9NZQ7-3: 20454 Da (predicted); Q9NZQ7-4: 28050 Da (predicted).
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8; leading to degradation. Deubiquitinated by USP22; leading to stabilization

Interacts with PDCD1. Interacts (via transmembrane domain) with CMTM4 and CMTM6. Interacts with (phosphorylated) STAT3; promoting nuclear translocation. Interacts with CD80

Q9NZQ7

Programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD antigen CD274; CD274 nanobody; PD-L1 nanobody;